Canadian Cancer Society logo

Chronic myelogenous leukemia

You are here: 

Treatment for accelerated phase of chronic myelogenous leukemia

In the accelerated phase of chronic myelogenous leukemia (CML), the leukemia cells begin to build up more quickly and symptoms appear. New gene mutations are often acquired, which helps the leukemia cells grow and tends to make treatments less effective. The blood cell counts may be abnormal, the spleen may be enlarged and the person does not feel well.

The goal of treatment during this phase is to destroy all the cells that contain the BCR-ABL gene or to return the CML to the chronic phase. The treatment options are similar to those for the chronic phase. However, a long-term response to treatment is less likely.

Response to treatment is important and is closely monitored.

Stem cell transplant

A stem cell transplant may be offered for CML in the accelerated phase.

  • Allogeneic transplantAllogeneic transplantA type of stem cell transplant that uses blood-forming stem cells collected from circulating (peripheral) blood, rather than from bone marrow. can bring about remission in some people.
  • Doctors usually prefer that the leukemia returns to the chronic phase or is controlled before the transplant.
  • Sometimes an autologous transplantautologous transplantA type of stem cell transplant that uses blood-forming stem cells collected from circulating (peripheral) blood, rather than from bone marrow. is an option to try to return the CML to the chronic phase.
  • A reduced-intensity transplant may be an option for older people who may not tolerate a standard transplant.
    • The chemotherapy or radiation used to prepare for a stem cell transplant is less intense than that used for a standard allogeneic transplant.

Targeted therapy

Targeted therapy with a tyrosine kinase inhibitor may be offered during the accelerated phase of CML. For those already taking targeted therapy, the dose may be increased. The types of targeted therapy used are:

  • imatinib (Gleevec)
  • dasatinib (Sprycel)

Biological therapy

Biological therapy may be offered for CML in the accelerated phase. The most common type of biological therapy used is interferon alfa (Intron A, Roferon A). Interferon alfa may be given in combination with cytarabine (Cytosar, Ara-C).

Chemotherapy

Chemotherapy may be offered for CML in the accelerated phase. The types of chemotherapy used are:

  • cytarabine (Cytosar, Ara-C)
  • HDAC (high-dose cytarabine)
  • hydroxyurea (Hydrea, Gen-hydroxyurea, Apo-hydroxyurea)
  • busulfan (Myleran [oral], Busulfex [intravenous])

Clinical trials

People with CML may be offered the opportunity to participate in clinical trials. For more information, go to clinical trials.

Stories

Heather Moyes I encourage every woman – regardless of how young or how old – to be aware of their body

Read Heather's story

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more